BioSpace News Archive

Company Intends to Initiate Clinical Trials using Novel “Multipronged” Attack on Coronavirus Pathology

The first commercial sqid-X system sale to be used to triage COVID-19 patients in New York state

MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. Food & Drug Administration (FDA) approval of an Investigational New Drug (IND) application for the GV-971 international multi-center Phase 3 clinical study in the treatment of patients with Alzheimer’s disease.

Industry veteran joins McKesson after more than 13 years at National Comprehensive Cancer Network

Isofol Medical AB, announced approval of a clinical patent for arfolitixorin in the United States.

Unique transdermal delivery technology and medicines for rare diseases combine to deliver significant quality-of-life benefits for patients

Crescendo Biologics Ltd, the developer of novel, targeted, T cell enhancing therapeutics, and Cancer Research UK, the world’s largest independent funder of cancer research, announce a Clinical Development Partnership to progress one of Crescendo’s novel bispecific Humabody® immunotherapies, CB213, into clinical trials targeting cancers of high unmet medical need.

Mateon Therapeutics Inc. announced that the US Food and Drug Administration granted Rare Pediatric Disease Designation for CA4P/ Fosbretabulin for the treatment of of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients as a drug for a “rare pediatric disease”.

Haemonetics Corporation announced that financial results for its fourth quarter and fiscal 2020, which ended March 28, 2020, are available on its Investor Relations website.

Regeneron Pharmaceuticals, Inc. announced financial results for the first quarter of 2020 and provided a business update..